The story so far · 2 days, November 10 to 11, 2026
FDA orders eye-risk warnings on GLP-1 drugs
One Turn followed this story across 2 editions, from Silver Spring, United States on November 10, 2026. Newest first.
These drugs are sold under brands such as Ozempic and Mounjaro.
Open the latest on the 3D globe →
Day by day
- FDA adds eye risk warning to GLP-1 drugs
- FDA orders eye-risk warnings on GLP-1 drugs
Every installment
Wednesday, November 11, 2026 · Day 2 · Health · Silver Spring, Maryland · United States of America
The FDA told makers of semaglutide and tirzepatide to warn about a rare optic nerve disorder that can cause permanent vision loss.
Why it matters: Millions use these drugs for diabetes and weight loss.
Sources: BBC News via Wikipedia · See it on the globe
Tuesday, November 10, 2026 · Day 1 · Health · Silver Spring, United States · United States of America
The FDA ordered makers of Ozempic, Wegovy and similar drugs to add warnings about NAION, a rare optic nerve condition that can cause blindness.
Why it matters: Millions use these drugs and should know the risk.
Sources: CNBC, BBC News, BBC News via Wikipedia · See it on the globe
Where
More running stories →